EA201992414A1 - Комбинация nk1-антагониста и способ лечения синуклеинопатий - Google Patents

Комбинация nk1-антагониста и способ лечения синуклеинопатий

Info

Publication number
EA201992414A1
EA201992414A1 EA201992414A EA201992414A EA201992414A1 EA 201992414 A1 EA201992414 A1 EA 201992414A1 EA 201992414 A EA201992414 A EA 201992414A EA 201992414 A EA201992414 A EA 201992414A EA 201992414 A1 EA201992414 A1 EA 201992414A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
sinucleinopathies
antagonists
treating
propylamino
Prior art date
Application number
EA201992414A
Other languages
English (en)
Inventor
Томас Н. Чейс
Кэтлин Э. Клэренс-Смит
Original Assignee
Чейс Терапьютикс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чейс Терапьютикс Корпорейшн filed Critical Чейс Терапьютикс Корпорейшн
Publication of EA201992414A1 publication Critical patent/EA201992414A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)

Abstract

Настоящее изобретение описывает применение NK1-антагониста в комбинации с 6-пропиламино-4,5,6,7-тетрагидро-1,3-бензотиазол-2-амином для облегчения лечения пациента, страдающего синуклеинопатией, позволяющее применять терапевтически эффективную суточную дозу 6-пропиламино-4,5,6,7-тетрагидро-1,3-бензотиазол-2-амина без типичных нежелательных явлений, вызываемых прамипексола дигидрохлорида моногидратом при его отдельном применении.
EA201992414A 2017-04-10 2018-04-09 Комбинация nk1-антагониста и способ лечения синуклеинопатий EA201992414A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483555P 2017-04-10 2017-04-10
PCT/US2018/026699 WO2018191160A1 (en) 2017-04-10 2018-04-09 Nk1-antagonist combination and method for treating synucleinopathies

Publications (1)

Publication Number Publication Date
EA201992414A1 true EA201992414A1 (ru) 2020-03-16

Family

ID=63792736

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992414A EA201992414A1 (ru) 2017-04-10 2018-04-09 Комбинация nk1-антагониста и способ лечения синуклеинопатий

Country Status (14)

Country Link
US (1) US11160809B2 (ru)
EP (1) EP3609495A4 (ru)
JP (1) JP7271437B2 (ru)
KR (1) KR20200002899A (ru)
CN (1) CN110730662A (ru)
AU (1) AU2018251604B2 (ru)
BR (1) BR112019021125A2 (ru)
CA (1) CA3059418A1 (ru)
EA (1) EA201992414A1 (ru)
IL (3) IL309770A (ru)
MA (1) MA51658A (ru)
MX (1) MX2019012088A (ru)
TW (1) TWI803488B (ru)
WO (1) WO2018191160A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200026920A (ko) * 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186087B1 (de) 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE122006000066I2 (de) 1991-05-31 2007-12-06 Pfizer Chinuclidinderivate
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EP0942732B1 (en) * 1996-12-02 2004-11-17 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating movement disorders
DE19830201A1 (de) 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (de) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
SI1303490T1 (sl) 2000-07-14 2008-10-31 Hoffmann La Roche N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
DE60123661T2 (de) 2000-12-14 2007-08-16 F. Hoffmann-La Roche Ag Selbstemulgierende lipidmatrix (selm)
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
LT1713504T (lt) 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
US20120253047A1 (en) 2004-03-19 2012-10-04 Dipharma S.P.A. Process for the preparation of (r)-pramipexole
EA014239B1 (ru) * 2005-03-08 2010-10-29 Янссен Фармацевтика Н.В. Производные диаза-спиро-[4,4]нонана в качестве антагонистов нейрокинина (nk1)
WO2007008564A1 (en) 2005-07-11 2007-01-18 Merck & Co., Inc. Process for making hydroisoindoline tachykinin receptor antagonists
ES2334061T3 (es) 2005-08-15 2010-03-04 University Of Virginia Patent Foundation Neurorrestauracion con pramipexol r(+).
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
CN101641096A (zh) * 2006-12-14 2010-02-03 诺普神经科学股份有限公司 (r)-普拉克索的组合物以及使用该组合物的方法
JP2010521493A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． （６ｒ）−４，５，６，７−テトラヒドロ−ｎ６−プロピル−２，６−ベンゾチアゾール−ジアミンの放出調節製剤およびそれらの使用方法
US20080254117A1 (en) 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
JP5860399B2 (ja) 2009-08-14 2016-02-16 オプコ ヘルス， インコーポレイテッド ニューロキニン−１アンタゴニストの静脈内用製剤
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
WO2012140604A1 (en) 2011-04-15 2012-10-18 Sandoz Ag Stable formulations of pramipexole hydrochloride
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
WO2015054429A1 (en) 2013-10-08 2015-04-16 Innopharma, Inc Aprepitant oral liquid formulations
KR102424837B1 (ko) 2014-09-19 2022-07-25 헤론 테라퓨틱스 인코포레이티드 아프레피탄트의 에멀젼 제형
US9850267B2 (en) 2015-06-03 2017-12-26 Navinta, Llc Crystalline fosaprepitant dicyclohexylamine salt and its preparation
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
KR20200026920A (ko) * 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법

Also Published As

Publication number Publication date
MA51658A (fr) 2020-12-02
US11160809B2 (en) 2021-11-02
CA3059418A1 (en) 2018-10-18
IL269875B2 (en) 2024-06-01
IL309770A (en) 2024-02-01
AU2018251604A1 (en) 2019-11-21
IL269875B1 (en) 2024-02-01
CN110730662A (zh) 2020-01-24
KR20200002899A (ko) 2020-01-08
TW201841634A (zh) 2018-12-01
US20200147097A1 (en) 2020-05-14
EP3609495A1 (en) 2020-02-19
TWI803488B (zh) 2023-06-01
WO2018191160A1 (en) 2018-10-18
JP7271437B2 (ja) 2023-05-11
MX2019012088A (es) 2020-02-07
IL269875A (ru) 2019-12-31
JP2020516625A (ja) 2020-06-11
AU2018251604B2 (en) 2022-04-14
BR112019021125A2 (pt) 2020-05-12
EP3609495A4 (en) 2020-12-02
IL312486A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
EA201591290A2 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
EA201991650A1 (ru) Способы лечения неврологических расстройств
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2021002322A (es) Nuevos metodos.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA202193276A1 (ru) Способы лечения холангиокарциномы
EA202090180A1 (ru) Композиции nk1-антагониста и способы лечения депрессии
FR3084254B1 (fr) Derives deuteres du lanifibranor
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
ZA201907101B (en) Methods of preventing or treating ophthalmic diseases
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
PH12019501566A1 (en) Amide compounds and use thereof
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
EA201992414A1 (ru) Комбинация nk1-антагониста и способ лечения синуклеинопатий
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2019004200A (es) Terapia de combinacion.